EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study

Mohammad Jay iD, Iliana C Lega, Noemie Villemure-Poliquin, Cristina Goens, Afshan Zahedi

Journal of the Endocrine Society · 03.06.2026 · 10 (7)

DOI: 10.1210/jendso/bvag066 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the Endocrine Society, online erschienen am 24.03.2026. Verfasst von Mohammad Jay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The optimal radioactive iodine (RAI) activity for intermediate-risk papillary thyroid cancer (PTC) remains uncertain, and evidence to guide individualized treatment is limited.

Objective

To compare recurrence between moderate- and high-activity RAI and to identify clinicopathologic factors associated with persistent or recurrent disease.

Methods

We conducted a retrospective cohort study of adults with intermediate-risk PTC treated at a tertiary academic thyroid cancer clinic between 2010 and 2022. Patients received moderate-activity RAI, defined as 30 to 90 mCi, or high-activity RAI, defined as greater than 90 mCi, as initial postoperative therapy. The primary outcome was time to recurrence. The secondary outcome was a composite of persistent or recurrent disease at last follow-up.

Results

Among 181 patients, 94 received moderate-activity RAI and 87 received high-activity RAI. Over a median follow-up of 52 months, 18 recurrences occurred (crude: 3/94 vs 15/87). High-activity RAI was not associated with improved recurrence-free survival (inverse probability of treatment weighting [IPTW]-weighted hazard ratio 2.73; 95% confidence interval [CI] 0.74 to 10.01). Persistent or recurrent disease occurred in 61 patients (34%) with no association in IPTW models (hazard ratio 0.97; 95% CI 0.53 to 1.76). Extranodal extension, microscopic extrathyroidal extension, larger lymph node deposit size, and older age were associated with persistent or recurrent disease.

Conclusion

High-activity RAI was not associated with improved recurrence versus moderate-activity in intermediate-risk PTC. This study is among the first to evaluate moderate-activity RAI as a distinct comparator. Findings support moderate-activity RAI as a reasonable risk-adapted approach. Prospective studies are needed to validate these results.

Schlagwörter

Stichwörter der Autor:innen

disease recurrencepapillary thyroid cancerprognostic factorsradioactive iodine doseradioactive iodine therapyrecurrence-free survival

Autor:innen und Institutionen

  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Mohammad Jay

Zitieren

APA

Jay, M., Lega, I. C., Villemure-Poliquin, N., Goens, C., & Zahedi, A. (2026). Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study. Journal of the Endocrine Society, 10(7). https://doi.org/10.1210/jendso/bvag066

Vancouver

Jay M, Lega IC, Villemure-Poliquin N, Goens C, Zahedi A. Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study. Journal of the Endocrine Society. 2026;10(7). doi:10.1210/jendso/bvag066

BibTeX
@article{Jay2026,
  author = {Jay, Mohammad and Lega, Iliana C and Villemure-Poliquin, Noemie and Goens, Cristina and Zahedi, Afshan},
  title = {Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study},
  journal = {Journal of the Endocrine Society},
  year = {2026},
  volume = {10},
  number = {7},
  doi = {10.1210/jendso/bvag066}
}
Kostenlos starten →